Navigation Links
Nobilis Therapeutics Announces FDA Clearance of IND to Commence Phase 2b Trial of NBTX-001 Inhaler for Treatment of Posttraumatic Stress Disorder
Date:12/6/2019

Nobilis Therapeutics, a clinical stage biotechnology company focused on development of treatments for psychiatric and neurodegenerative disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NBTX-001 Inhaler, allowing the Company to initiate its Phase 2b trial for the treatment of patients with Posttraumatic Stress Disorder (PTSD).

“FDA clearance of the IND for NBTX-001 drug-device combination signifies a critical milestone for Nobilis Therapeutics, as it validates its novel approach to treatment of PTSD” said Dr. Vlad Bogin, Company’s Founder and Chief Executive Officer. “Patients with this devastating illness suffer from severely depressed quality of life, deterioration of marital and family relationships, substance abuse and suicidality. Our clinical program is aimed to address not just the symptoms, but the pathophysiology of PTSD.”

Dr. Kerry Ressler, MD, PhD, Professor of Psychiatry at Harvard Medical School, CSO, James and Patricia Poitras Chair in Psychiatry at McLean Hospital, and a Principle investigator of the trial stated: “I am very excited to be helping to lead the NBTX-001 Inhaler trial. I believe that the drug’s competitive inhibition of NMDA receptors, that appears to block trauma memory reconsolidation, may represent an important advance in the treatment of PTSD, a disease with tremendous unmet need for effective medicines.”

NBTX-001 will be a prospective, multicenter, randomized, double-blinded, placebo-controlled phase 2b study that will enroll 190 patients in approximately 25 sites in the United States. The primary endpoint of the study is the mean change from baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score.

About Posttraumatic Stress Disorder
Posttraumatic Stress Disorder is a devastating psychiatric condition associated with tremendous emotional and financial costs to the health care system. It is estimated that approximately 6.1% of Americans will suffer from PTSD at one point in their lives, with significantly higher proportions in war veterans suffering from PTSD (approximately 12% to 30%).

Currently the main treatment interventions for PTSD include psychotropic medications and/or psychotherapy. The selective serotonin reuptake inhibitor (SSRI) antidepressants, sertraline and paroxetine, are the only US Food and Drug Administration (FDA) approved medications for the condition that show limited clinical improvement in PTSD sufferers. National Center for PTSD (NCPTSD) treatment guideline recommends Exposure Therapy as one of the most robust treatments. However, although it has shown to be efficacious for treatment of PTSD, a recent randomized clinical study in 370 military personnel with PTSD showed relatively modest reductions in PTSD symptom severity.

PTSD remains a disease with tremendous unmet need currently with only limited effective treatments.

About Nobilis Therapeutics, Inc.
Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using portable controlled device administration of inert gases. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric, neurodegenerative and other diseases and leverages the experience of its international team that has studied this technology in the treatment of over 2500 patients for conditions ranging from panic attacks to substance abuse. Company’s first clinical trial in 81 patients with Panic Disorder showed significant signals of efficacy. In 2016 the Company entered into an exclusive licensing agreement with Harvard University on the use of NBTX-001 in PTSD and had a patent issued the next year. Of its 14 independently filed patents 3 have been issued. In January of 2019 the Company had entered into collaboration with Linde AG to support its medical device and clinical development program.

Contact:
Vlad Bogin, MD, FACP
US Bancorp Tower, 111 S.W. Fifth Avenue, Suite 3150, Portland, OR, 97204, USA
Tel: (971) 229-1679
Email: info@nobilistx.com
Website: http://www.nobilistx.com
Twitter: @nobilistx

Read the full story at https://www.prweb.com/releases/nobilis_therapeutics_announces_fda_clearance_of_ind_to_commence_phase_2b_trial_of_nbtx_001_inhaler_for_treatment_of_posttraumatic_stress_disorder/prweb16770672.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
2. Novelos Therapeutics Provides Product Pipeline Update
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
4. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
6. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
7. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
8. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
9. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
10. Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
11. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2020)... NEW YORK (PRWEB) , ... January 23, 2020 ... ... spectrum disorder (ASD) to date, researchers have identified 102 genes associated with risk ... associated with ASD from those associated with intellectual disability and developmental delay, conditions ...
(Date:1/23/2020)... ... January 23, 2020 , ... For ... Australian Dream® for effective relief. Now, the company is unveiling new packaging ... sought to develop a new design that better communicates the quality and benefits ...
(Date:1/23/2020)... ... January 23, 2020 , ... EBSCO ... announced the availability of a new decision aid within its shared decision making ... to manage opioid addiction. , Opioid addiction is a chronic relapsing condition of ...
Breaking Medicine Technology:
(Date:1/24/2020)... (PRWEB) , ... January 24, 2020 , ... ... Secours Mercy Health Our Lady of Bellefonte Hospital (OLBH) achieved a 59 percent ... goal established by the Centers for Disease Control and Prevention. , The retrospective ...
(Date:1/23/2020)... ... January 23, 2020 , ... The Mount Sinai Health System has once again ... , Mount Sinai was ranked No. 3 in the “Healthcare & Social” category and ... is New York City’s largest academic medical system, including eight hospitals, a leading medical ...
(Date:1/23/2020)... ... 2020 , ... Worldwide Business with kathy ireland® is pleased to ... Vice President of Dairy and Frozen, Jimmy Farber to discuss their healthy, affordable all ... food and snack options at an affordable price. The company believes that the best ...
(Date:1/23/2020)... ... January 23, 2020 , ... Merger and acquisition activity in the ... of 2019, according to data from HealthCareMandA.com. The total is the lowest reported in ... when 65 deals were announced. , One deal disclosed a price in the fourth ...
(Date:1/23/2020)... ... January 23, 2020 , ... ... services for organizations that operate vehicle fleets in North America and around the ... will be published monthly with content accessible on the company’s website. , Developed ...
Breaking Medicine News(10 mins):